Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?

Endocrine

Volumn 48, Issue 1, 2015, Pages 47-52

  Cao, Yang ^a   Liu, Xiao Min ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Gastrin; Glucagon like peptide 1 receptor (GLP 1R) agonists; Proton pump inhibitor (PPI); Thyroid C cells

Indexed keywords

ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR;

AGONISTS; ANIMAL; CYTOLOGY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HUMAN; THYROID GLAND;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON; THYROID GLAND;

EID: 84939877797     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0354-3     Document Type: Review

References (41)

1. S. Mojsov, G.C. Weir, J.F. Habener, Insulinotropin: glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79, 616–619 (1987)
2. L.R. Ranganath, Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J. Clin. Pathol. 61, 401–409 (2008)
3. A. Maida, T. Hansotia, C. Longuet, Y. Seino, D.J. Drucker, Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 137, 2146–2157 (2009)
4. K.J. Hare, F.K. Knop, M. Asmar, S. Madsbad, C.F. Deacon, J.J. Holst, T. Vilsbøll, Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94, 4679–4687 (2009)
5. T. Talsania, Y. Anini, S. Siu, D.J. Drucker, P.L. Brubaker, Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146, 3748–3756 (2005)
6. M. Tang-Christensen, N. Vrang, P.J. Larsen, Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int. J. Obes. Relat. Metab. Disord. 25(Suppl. 5), S42–S47 (2001)
7. H. Linnebjerg, S. Park, P.A. Kothare, M.E. Trautmann, K. Mace, M. Fineman, I. Wilding, M. Nauck, M. Horowitz, Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 151, 123–129 (2008)
8. R.A. DeFronzo, T. Okerson, P. Viswanathan, X.S. Guan, J.H. Holcombe, L. MacConell, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 24, 2943–2952 (2008)
9. L. Bjerre Knudsen, L.W. Madsen, S. Andersen, K. Almholt, A.S. Boer, D.J. Drucker, C. Gotfredsen, F.L. Egerod, A.C. Hegelund, H. Jacobsen, S.D. Jacobsen, A.C. Moses, A.M. Mølck, Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473–1486 (2010)
10. L.W. Madsen, J.A. Knauf, C. Gotfredsen, A. Pilling, I. Sjögren, S. Andersen, L. Andersen, A.S. Boer, K. Manova, A. Barlas, S. Vundavalli, N.C. Nyborg, L.B. Knudsen, A.M. Moelck, J.A. Fagin, GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153, 1538–1547 (2012)
11. M. Parks, C. Rosebraugh, Weighing risks and benefits of liraglutide-The FDA’s review of a new antidiabetic therapy. N. Engl. J. Med. 362, 774–777 (2010)
12. Y. Lamari, C. Boissard, M.S. Moukhtar, A. Jullienne, G. Rosselin, J.M. Garel, Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 393, 248–252 (1996)
13. B. Gier, P.C. Butler, C.K. Lai, D. Kirakossian, M.M. DeNicola, M.W. Yeh, Glucagon like peptide-1 receptor expression in the human thyroid gland. J. Clin. Endocrinol. Metab. 97, 121–131 (2012)
14. B. Waser, K. Beetschen, N.S. Pellegata, J.C. Reubi, Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94, 291–301 (2011)
15. L. Hegedus, A.C. Moses, M. Zdravkovic, T.L. Thi, G.H. Daniels, GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J. Clin. Endocrinol. Metab. 96, 853–860 (2011)
16. M. Gallo, Thyroid safety in patients treated with liraglutide. J. Endocrinol. Invest. 36, 140–145 (2013)
17. A.A. Zayed, M. Alzubaidi, S. Atallah, M.S. Momani, W.K. Al-Delaimy, Should food intake and circadian rhythm be considered when measuring serum calcitonin level? Endocr Pract. 19, 620–626 (2013)
18. D. Bulchandani, J.S. Nachnani, B. Herndon, A. Molteni, M.H. Pathan, T. Quinn, H.A. Hamdan, L.M. Alba, L. Graves, Effect of exendin (exenatide)-GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model. Eur. J. Pharmacol. 691, 292–296 (2012)
19. M. Blaker, P. Arrenberg, I. Stange, M. Schulz, S. Burghardt, H. Michaelis, A. Pace, H. Greten, T. Schrenck, A. Weerth, The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT. Regul. Pept. 118, 111–117 (2004)
20. T.C. Wang, S. Bonner-Weir, P.S. Oates, M. Chulak, B. Simon, G.T. Merlino, E.V. Schmidt, S.J. Brand, Pancreatic gastrin stimulates islet differentiation of transforming growth factor to induced ductular precursor cells. J. Clin. Invest. 92, 1349–1356 (1993)
21. G. Xu, S. Sumi, M. Koike, K. Tanigawa, Y. Nio, K.T. Mura, Role of endogenous hypergastrinemia in regenerating endocrine pancreas after partial pancreatectomy. Dig. Dis. Sci. 41(12), 2433–2439 (1996)
22. T.B. Bödvarsdóttir, K.D. Hove, C.F. Gotfredsen, L. Pridal, A. Vaag, A.E. Karlsen, J.S. Petersen, Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53, 2220–2223 (2010)
23. W.L. Suarez-Pinzon, R.F. Power, Y.H. Yan, C. Wasserfall, M. Atkinson, A. Rabinovitch, Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57, 3281–3288 (2008)
24. W.L. Suarez-Pinzon, G.S. Cembrowski, A. Rabinovitch, Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52, 1680–1682 (2009)
25. K. Fosgerau, L. Jessen, J.L. Tolborg, T. Østerlund, K.S. Larsen, K. Rolsted, M. Brorson, J. Jelsing, T.S.R. Neerup, The novel GLP-1-gastrin dual agonist, ZP3022, increases β -cell mass and prevents diabetes in db/db mice. Diabetes Obes. Metab. 15, 62–71 (2013)
26. P.K. Singh, D. Hota, P. Dutta, N. Sachdeva, A. Chakrabarti, A. Srinivasan, I. Singh, A. Bhansali, Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 97, E2105–E2108 (2012)
27. J.C. Reubi, J.C. Schaer, B. Waser, Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 57, 1377–1386 (1997)
28. G. Vitale, A. Ciccarelli, M. Caraglia, M. Galderisi, R. Rossi, S.D. Prete, A. Abbruzzese, G. Lupoli, Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin. Chem. 48, 1505–1510 (2002)
29. B.A. Roos, L.J. Deftos, Regulation of calcitonin secretion in vitro. Clin Endocrinol. Suppl.5, 217s–222s (1976)
30. G.W. Sizemore, V.L.W. Go, E.L. Kaplan, L.J. Sanzenbacher, K.H. Holtermuller, C.D. Arnaud, Relations of calcitonin and gastrin in the Zollinger–Ellison syndrome and medullary carcinoma of the thyroid. N. Engl. J. Med. 288, 641–644 (1973)
31. C. Owyang, H. Heath, G.W. Sizemore, V.L. Go, Comparison of the effects of pentagastrin and meal-stimulated gastrin on plasma calcitonin in normal man. Am J Dig Dis.23, 1084–1088 (1978)
32. C.B. Lamers, W.H. Hackeng, T. Thien, J.H. Tongeren, Serum concentrations of immunoreactive calcitonin in patients with hypergastrinemia. Digestion 20, 379–382 (1980)
33. M.F. Erdogan, A. Gursoy, M. Kulaksizoglu, Long-term effects of elevated gastrin levels on calcitonin secretion. J. Endocrinol. Invest. 29, 771–775 (2006)
34. E. Bertin, N. Schneider, N. Abdelli, H. Wampach, G. Cadiot, A. Loboguerrero, M. Leutenegger, J.C. Liehn, G. Thiefin, Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy. Diabetes Metab. 27, 357–364 (2001)
35. I. Migdalis, T. Thomaides, C. Chairopoulos, C. Kalogeropoulou, J. Charalabides, F. Mantzara, Changes of gastric emptying rate and gastrin levels are early indicators of autonomic neuropathy in type II diabetic patients. Clin. Auton. Res. 11, 259–263 (2001)
36. V. Patel, A. Joharapurkar, T. Gandhi, K. Patel, N. Dhanesha, S. Kshirsagar, V. Dhote, J. Detroja, R. Bahekar, M. Jain, Omeprazole improves the antiobesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. J diabetes. 5(2), 163–171 (2013)
37. R. Eissele, E. Bothe-Sandfort, B. Göke, J. Eng, R. Arnold, H. Koop, Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci. 55, 629–634 (1994)
38. X. Jia, J.C. Brown, Y.N. Kwok, R.A. Pederson, C.H. McIntosh, Gastric inhibitory polypeptide and glucagon-like peptide-1 (7–36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. Can. J. Physiol. Pharmacol. 72, 1215–1219 (1994)
39. R. Eissele, H. Koop, R. Arnold, Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. Scand. J. Gastroenterol. 25, 449–454 (1990)
40. Food and Drug Administration, Forteo (teriparatide), medical review 2002: Part 3. (2002). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_FORTEO_Medr_P3.pdf
41. V. Thurston, E.D. Williams, Experimental induction of C cell tumours in thyroid by increased dietary content of vitamin D3. Acta Endocrinol. 100, 41–45 (1982)